000			nab a22 7a 4500
999			_c17464 _d17464
003			PC17464
005			20230519115831.0
008			230519b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91233 _aHernández Hernández, Felipe _eCardiología
245	0	0	_aTwo-year clinical outcome from the Iberian registry patients after left atrial appendage closure. _h[artículo]
260			_bHeart (British Cardiac Society), _c2015
300			_a101(11):877-83.
500			_aFormato Vancouver: López Mínguez JR, Asensio JM, Gragera JE, Costa M, González IC, de Carlos FG et al. Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. Heart. 2015 Jun;101(11):877-83.
501			_aPMID: 25573984
504			_aContiene 30 referencias
520			_aAims: The aim of this study was to observe the percentage of thromboembolic and haemorrhagic events over a 2-year follow-up in patients with non-valvular atrial fibrillation (NVAF) undergoing closure of the left atrial appendage (LAA) with an occlusion device. Observed events and CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke history), CHA2DS2-VASc (also adding: vascular disease and sex) and HAS-BLED (hypertension, abnormal liver/renal function, stroke history, bleeding predisposition, labile international normalised ratios, elderly, drugs/alcohol use)-predicted events were compared. Methods: LAA closure with an occlusion device was performed in 167 NVAF patients contraindicated for oral anticoagulants and recruited from 12 hospitals between 2009 and 2013. At least two transoesophageal echocardiograms were performed in the first 6 months postimplantation. Antithrombotics included clopidogrel and aspirin. Patients were monitored for death, stroke, major and relevant bleeding and hospitalisation for concomitant conditions. Mean age was 74.68±8.58, median follow-up was 24 months, 5.38% had intraoperative complications and implantation was successful in 94.6% of subjects. Mortality during follow-up was 10.8%, mostly (9.5%) non-cardiac related. Bleeding occurred in 10.1% of subjects, 5.7% major and 4.4% minor though relevant, and 4.4% suffered stroke. Major bleeding and stroke/transient ischaemic attack events within 2 years (annual event rates, 290 patients/year) were less frequent than expected from CHADS2 (2.4% vs 9.6%), CHA2DS2-VASc (2.4% vs 8.3%) and HAS-BLED (3.1% vs 6.6%) risk scores (p<0.001, p=0.003, p=0.047, respectively). Conclusions: LAA closure with an occlusion device in patients contraindicated for oral anticoagulants is a therapeutic option associated with fewer thromboembolic and haemorrhagic events than expected from risk scores, particularly in the second year postimplantation.
710			_9119 _aServicio de Cardiología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17464.pdf _ySolicitar documento
942			_2ddc _cART _n0